Review
Biochemistry & Molecular Biology
Lauren M. Kreps, Christina L. Addison
Summary: Metastasis to the bone is a common and incurable feature of many cancers. The process involves tumor cells entering the circulation and then the bone, where they may be inhibited from growth by the bone microenvironment. Understanding the complex interactions between tumor cells and bone resident cells in this microenvironment could lead to new therapies for bone metastases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Antonia Sophocleous, Michael Yiallourides, Feier Zeng, Pantelis Pantelas, Eleni Stylianou, Boya Li, Giovana Carrasco, Aymen I. Idris
Summary: Research on the modulation of CB1 and CB2 receptors on bone metabolism has shown that the results are confounded by the heterogeneity of models and the low number of studies.
PHARMACOLOGICAL RESEARCH
(2022)
Article
Medicine, General & Internal
Karim Fizazi, Josep M. Piulats, M. Neil Reaume, Peter Ostler, Ray McDermott, Joel R. Gingerich, Elias Pintus, Srikala S. Sridhar, Richard M. Bambury, Urban Emmenegger, Henriette Lindberg, David Morris, Franco Nole, John Staffurth, Charles Redfern, Maria I. Saez, Wassim Abida, Gedske Daugaard, Axel Heidenreich, Laurence Krieger, Brieuc Sautois, Andrea Loehr, Darrin Despain, Catherine A. Heyes, Simon P. Watkins, Simon Chowdhury, Charles J. Ryan, Alan H. Bryce
Summary: In this Phase 3 trial, the PARP inhibitor rucaparib demonstrated significant activity in patients with metastatic, castration-resistant prostate cancer with a deleterious BRCA alteration. The duration of imaging-based progression-free survival was significantly prolonged in the rucaparib group compared to the control group.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Urology & Nephrology
Berdine L. Heesterman, Henk G. van der Poel, Ivo G. Schoots, Niven Mehra, Katja K. H. Aben
Summary: This study evaluated the prognostic importance of concomitant non-regional lymph node and bone metastases in men with synchronous metastatic hormone-sensitive prostate cancer. It found that in low-volume disease, the presence of these metastases was a poor prognostic sign, while survival was worse for men with visceral metastases. This implies a need to reconsider the classification of metastatic burden.
Review
Cell Biology
Sharon Russo, Federica Scotto di Carlo, Fernando Gianfrancesco
Summary: Osteoclasts play an important role in bone remodeling, but they are also involved in bone tumors and metastases. They increase the aggressiveness of primary tumors and promote metastasis of breast and pancreas cancer cells to the bone. Additionally, osteoclasts are responsible for reactivating dormant cancer cells in the bone marrow, leading to overt metastasis.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Health Care Sciences & Services
Omar Fahmy, Nabil A. Alhakamy, Mohd G. Khairul-Asri, Osama A. A. Ahmed, Usama A. Fahmy, Claudia G. Fresta, Giuseppe Caruso
Summary: Checkpoint inhibitors provide modest oncological advantages in metastatic castration-resistant prostate cancer. Currently, there are no good predictive indicators for a greater response.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Sport Sciences
Pedro Lopez, Dennis R. Taffe, Robert U. Newton, Daniel A. Galvao
Summary: Resistance exercise improves various aspects of health for prostate cancer patients. Lower volume at moderate to high intensity is as effective as higher volume training for enhancing body composition, physical function, and muscle strength in the short term. A low exercise dosage may help improve exercise adherence for untrained older men with prostate cancer.
MEDICINE & SCIENCE IN SPORTS & EXERCISE
(2021)
Review
Endocrinology & Metabolism
Mainak Banerjee, Rimesh Pal, Satinath Mukhopadhyay
Summary: The meta-analysis suggests that the use of SGLT2 inhibitors may reduce the risk of gout events in patients with type 2 diabetes mellitus and decrease the need for anti-gout medication. This finding is important for the prevention of gout-related adverse events.
ACTA DIABETOLOGICA
(2022)
Article
Cell Biology
Fumihiko Urabe, Nobuyoshi Kosaka, Yusuke Yamamoto, Kagenori Ito, Kurataka Otsuka, Carolina Soekmadji, Shin Egawa, Takahiro Kimura, Takahiro Ochiya
Summary: Bone metastases are a major concern for prostate cancer patients, leading to complications and decreased survival. Recent studies have found that extracellular vesicles (EVs) are involved in tumor progression. This study demonstrates that EVs from metastatic prostate cancer cells promote osteoclast formation, and the transmembrane protein CDCP1 is identified as an inducer of this process. Furthermore, CDCP1 expression on EVs may serve as a potential biomarker for detecting bone metastasis in prostate cancer.
JOURNAL OF EXTRACELLULAR VESICLES
(2023)
Article
Oncology
Mihaela Aldea, Laurent Lam, Emeline Orillard, Casilda Llacer Perez, Mathilde Saint-Ghislain, Gwenaelle Gravis, Aude Flechon, Guilhem Roubaud, Philippe Barthelemy, Francesco Ricci, Frank Priou, Zoe Neviere, Mathilde Beaufils, Brigitte Laguerre, Anne-Claire Hardy, Carole Helissey, Raffaele Ratta, Delphine Borchiellini, Cedric Pobel, Florence Joly, Elena Castro, Antoine Thiery-Vuillemin, Giulia Baciarello, Karim Fizazi
Summary: The study suggests that cabazitaxel is effective in patients with mCRPC regardless of their DNA damage repair (DDR) status, although its efficacy may be lower in men pretreated with PARPi.
EUROPEAN JOURNAL OF CANCER
(2021)
Review
Chemistry, Medicinal
Sophia Ogechi Ekeuku, Kok-Lun Pang, Kok-Yong Chih
Summary: Caffeic acid, a metabolite of hydroxycinnamate and phenylpropanoid, acts as an antioxidant to reduce osteoclastogenesis and bone resorption. However, in some cases, it may have no effect on bone resorption or even impair bone mechanical properties in normal rats.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Endocrinology & Metabolism
Julian Hazelton, Seongho Kim, Julie L. Boerner, Izabela Podgorski, Timothy Perk, Frank Cackowski, Hussein D. Aoun, Elisabeth I. Heath
Summary: The study aimed to investigate potential racial differences in the distribution of tumor metastases in the bone. The results showed that there were no significant differences in the location and number of bone metastases based on race among patients with metastatic prostate cancer. Therefore, African American patients might derive similar benefits from molecular imaging as non-African American patients, given equal access to the technology.
Review
Urology & Nephrology
Keiichiro Mori, Hadi Mostafaei, Reza Sari Motlagh, Benjamin Pradere, Fahad Quhal, Ekaterina Laukhtina, Victor M. Schuettfort, Gero Kramer, Mohammad Abufaraj, Pierre I. Karakiewicz, Takahiro Kimura, Shin Egawa, Shahrokh F. Shariat
Summary: This study compared the efficacy and safety of currently available treatments for metastatic hormone-sensitive prostate cancer. The findings suggest that abiraterone, docetaxel, and enzalutamide are more effective than androgen-deprivation therapy in terms of overall survival, with abiraterone potentially being the best option.
Review
Oncology
Yuefu Zhan, Guangming Zhang, Mingliang Li, Xiaobo Zhou
Summary: The study compared the effectiveness of WBMRI and PET/CT in detecting bone metastases in patients with prostate cancer. PET/CT showed higher sensitivity and negative likelihood ratio for bone metastasis detection compared to WBMRI, while there were no differences in specificity and positive likelihood ratio.
FRONTIERS IN ONCOLOGY
(2021)
Review
Urology & Nephrology
Rashid K. Sayyid, Zachary Klaassen, Alejandro Berlin, Soumyajit Roy, Leonardo R. Brandao, Rui Bernardino, Julian Chavarriaga, Di Maria Jiang, Daniel E. Spratt, Neil E. Fleshner, Christopher J. D. Wallis
Summary: This study aimed to compare the effects of first-line poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) plus androgen receptor axis-targeted agents (ARAT) versus placebo/ARAT on radiographic progression-free survival (rPFS), overall survival (OS), and treatment-emergent adverse events (TEAEs) in patients with metastatic castrate-resistant prostate cancer (mCRPC). The results showed that adding PARPi to ARAT improved rPFS, particularly in BRCA1/2m patients. OS benefits were inconsistent and accompanied by an increase in severe TEAEs, especially anemia.
Article
Clinical Neurology
David L. Chan, Edward Hsiao, Geoff Schembri, Dale L. Bailey, Paul J. Roach, Adrian Lee, Dasantha Jayamanne, Mehrdad Ghasemzadeh, Aimee Hayes, Raymond Cook, Jonathon Parkinson, James P. Drummond, Imogen Ibbett, Helen R. Wheeler, Michael Back
JOURNAL OF CLINICAL NEUROSCIENCE
(2018)
Article
Endocrinology & Metabolism
Eric Baudin, Aimee R. Hayes, Jean-Yves Scoazec, Pier Luigi Filosso, Eric Lim, Gregory Kaltsas, Andrea Frilling, Jie Chen, Beata Kos-Kudla, Vera Gorbunova, Bertram Wiedenmann, Els Nieveen van Dijkum, Jaroslaw B. Cwikla, Jenny Falkerby, Juan W. Valle, Matthew H. Kulke, Martyn E. Caplin, Bartsch Detlef, Arnold Rudolf, Baudin Eric, Bodei Lisa, Borbath Ivan, Capdevila Jaume, Caplin Martyn, Chen Jie, Costa Frederico, Couvelard Anne, Cwikla B. Jaroslaw, Davies Philippa, Wouter W. de Herder, Falconi Massimo, Falkerby Jenny, Fazio Nicola, Ferone Diego, Frilling Andrea, Garcia-Carbonero Rocio, Glasberg Simona, Gorbunova Vera, Grossman Ashley, Hoech Dieter, Jensen Robert, Kaltsas Gregory, Kloeppel Guenter, Knigge Ulrich Peter, Kos-Kudla Beata, Krejs J. Guenter, Krenning Eric, Kulke Matthew, Lamberts W. J. Steven, Nieveen van Dijkum Elisabeth, O'Connor Juan Manuel, O'Toole Dermot, Pape Ulrich-Frank, Partelli Stefano, Pavel Marianne Ellen, Peeters Marc, Ramage John, Reed Nicholas Simon, Rindi Guido, Rinke Anja, Ruszniewski Philippe, Sorbye Halfdan, Sundin Anders, Scoazec Jean-Yves, Taal G. Babs, Tiensuu Janson Eva, Toumpanakis Christos, Valle Juan, Vullierme Marie-Pierre, Welin Staffan, Wiedenmann Bertram
NEUROENDOCRINOLOGY
(2019)
Article
Endocrinology & Metabolism
Ingrid Y. F. Mak, Aimee R. Hayes, Bernard Khoo, Ashley Grossman
NEUROENDOCRINOLOGY
(2019)
Article
Endocrinology & Metabolism
Man Liu, Eleni Armeni, Shaunak Navalkissoor, Joseph Davar, Luke Sullivan, Charlotte Leigh, Luke Furtado O'Mahony, Aimee Hayes, Dalvinder Mandair, Jie Chen, Martyn Caplin, Christos Toumpanakis
Summary: This study analyzed the clinical characteristics, management, and prognostic implications of cardiac metastases from neuroendocrine tumors in 25 patients. Conclusions indicate that concomitant bone or pancreatic metastases, as well as NT pro-BNP levels >2 upper limit of normal, are poor prognostic factors. Peptide receptor radionuclide therapy shows promise in improving patient survival.
NEUROENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Aimee R. Hayes, Ingrid Y. F. Mak, Nicholas Evans, Rishi Naik, Alexander Crawford, Bernard Khoo, Ashley B. Grossman, Shaunak Navalkissoor, Jennifer Watkins, Tu Vinh Luong, Dalvinder Mandair, Christos Toumpanakis, Christina Thirlwell, Martyn E. Caplin, Tim Meyer
Summary: This study suggests that PRRT is associated with superior clinical outcomes compared to other systemic therapies for G2 metastatic PNET patients. Prospective studies are needed to confirm these findings.
NEUROENDOCRINOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Luohai Chen, Shaunak Navalkissoor, Ann-Marie Quigley, Gopinath Gnanasegaran, Dalvinder Mandair, Christos Toumpanakis, Martyn E. Caplin, Aimee R. Hayes
Summary: In this study, patients aged 70 and older with advanced NET treated with Lu-177-DOTATATE showed efficacy and toxicity profiles similar to the broader NET population, without HRQoL deterioration.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Gastroenterology & Hepatology
Aimee R. Hayes, Myles Furnace, Ruchir Shah, Caroline Rundell, Gregory Muller, Hakim-Moulay Dehbi, Tu Vinh Luong, Christos Toumpanakis, Martyn E. Caplin, Daniel Krell, Christina Thirlwell, Dalvinder Mandair
Summary: The study identified two prognostically distinct subgroups within the grade 3 gastroenteropancreatic neuroendocrine neoplasms (GEP NEN) population: well-differentiated neuroendocrine tumors (WDNETs) and poorly differentiated neuroendocrine carcinomas (PDNECs). Patients with WDNETs had longer survival and higher response rates to first-line platinum-based chemotherapy. Definitive management pathways are needed to reflect the differences between G3 WDNETs and PDNECs.
Article
Endocrinology & Metabolism
Aimee R. Hayes, Alexander Crawford, Khulood Al Riyami, Christine Tang, Jamshed Bomanji, Stephanie E. Baldeweg, Damian Wild, Daniel Morganstein, Alice Harry, Simona Grozinsky-Glasberg, Kira Oleinikov, Bernard Khoo, Martyn E. Caplin, Guillaume P. Nicolas, Ashley B. Grossman
Summary: Ga-68-DOTA-SSA PET/CT has low detection rate of high tumor avidity in metastatic MTC patients, but PRRT may still be a viable treatment option for select patients.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Aimee R. Hayes, David L. H. Chan, Bryan A. Chan, Nick Pavlakis
Summary: The quality and reporting of neuroendocrine tumour (NET) clinical trials have been found to be heterogeneous in the past and have not significantly improved over time, despite advancements in our understanding of NET biology. Higher quality is observed in randomized trials, but certain design and reporting elements still need improvement. It is necessary to prioritize the design and conduct of NET clinical trials to inform future research effectively and guide changes in practice.
JOURNAL OF NEUROENDOCRINOLOGY
(2021)
Review
Oncology
Anna Angelousi, Aimee R. Hayes, Eleftherios Chatzellis, Gregory A. Kaltsas, Ashley B. Grossman
Summary: Medullary thyroid carcinoma (MTC) is a rare malignancy with limited treatment options. RET mutations are present in both familial and sporadic MTC. Targeted therapies, such as tyrosine kinase inhibitors, have shown promising results in recent years.
ENDOCRINE-RELATED CANCER
(2022)
Review
Endocrinology & Metabolism
Aimee R. Hayes, Ashley B. Grossman
Summary: In the context of ACTH-dependent Cushing's syndrome, ectopic ACTH secretion from a neuroendocrine tumour needs to be differentiated carefully from pituitary-dependent Cushing's syndrome, Cushing's disease, for optimal therapy. Diagnosis may be difficult as clinical and biochemical tests may overlap with Cushing's disease. Imaging is essential and should be interpreted considering both anatomical and functional imaging modalities.
JOURNAL OF NEUROENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Aimee R. Hayes, Tu Vinh Luong, Jamie Banks, Heer Shah, Jennifer Watkins, Eric Lim, Anant Patel, Ashley B. Grossman, Shaunak Navalkissoor, Daniel Krell, Martyn E. Caplin
Summary: DIPNECH may be more prevalent in the lung NET population than previously appreciated, especially in women. Although DIPNECH is predominantly associated with typical carcinoids, a portion of patients can develop atypical carcinoids and may require closer observation.
JOURNAL OF NEUROENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Tu Vinh Luong, Zaibun Nisa, Jennifer Watkins, Aimee R. Hayes
ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS
(2020)
Article
Endocrinology & Metabolism
Faidon-Marios Laskaratos, Eleni Armeni, Heer Shah, Maria Megapanou, Dimitrios Papantoniou, Aimee R. Hayes, Shaunak Navalkissoor, Gopinath Gnanasegaran, Conrad von Stempel, Edward Phillips, Myles Furnace, Lukasz Kamieniarz, Margarita Kousteni, Tu Vinh Luong, Jennifer Watkins, Dalvinder Mandair, Martyn Caplin, Christos Toumpanakis
Article
Oncology
Aimee R. Hayes, Dasantha Jayamanne, Edward Hsiao, Geoffrey P. Schembri, Dale L. Bailey, Paul J. Roach, Mustafa Khasraw, Allison Newey, Helen R. Wheeler, Michael Back
PRACTICAL RADIATION ONCOLOGY
(2018)